CAJ | 학술논문

短疗程化疗联合受累野局部放疗(IFRT)是治疗局限期(Ⅰ～Ⅱ期)弥漫大B细胞淋巴瘤患者的重要方法,但对于放疗的价值,目前存在争议.含蒽环类药物的联合化疗虽然使部分患者有可能被治愈,但依然有患者面临死亡.于是,研究者努力尝试通过提高化疗剂量密度或强度来提高患者的生存,但对老年患者,则试图减少剂量或使用毒性低的药物来进一步提高患者的生存.另外放射免疫疗法、生物靶向治疗等多方面的研究也取得了一定进展.
단료정화료연합수루야국부방료(IFRT)시치료국한기(Ⅰ～Ⅱ기)미만대B세포림파류환자적중요방법,단대우방료적개치,목전존재쟁의.함은배류약물적연합화료수연사부분환자유가능피치유,단의연유환자면림사망.우시,연구자노력상시통과제고화료제량밀도혹강도래제고환자적생존,단대노년환자,칙시도감소제량혹사용독성저적약물래진일보제고환자적생존.령외방사면역요법、생물파향치료등다방면적연구야취득료일정진전.
Short course chemotherapy combined with local field radiotherapy (IFRT) is an important treatment for limited-stage (Ⅰ -Ⅱ)diffuse large B cell lymphoma patients,but the value of radiotherapy has been disputed.Some patients may be cured by combined chemotherapy which contains anthracycline,but there are some patients still facing death.Therefore,researchers try to improve survival of patients further by increasing the density or intensity of the chemotherapy dose,but attempt to reduce the dose or the use of low toxicity drugs for elderly patients.In addition,researches such as radioimmunotherapy and biological targeted therapy have made certain progress.